Purdue Pharma Explores Bankruptcy After Thousands of Lawsuits
OxyContin-maker Purdue Pharma LP is exploring bankruptcy to prepare for the thousands of lawsuits filed against the company, Reuters reported early this morning. An official statement has yet to be released by the private pharmaceutical …
JNJ Stock: Johnson & Johnson Misses Analyst Target for Forecast 2019 Sales
Johnson & Johnson (JNJ) (NYSE:JNJ) released its forecast 2019 sales earlier today. The pharmaceutical giant fell short of analyst estimates after previously reporting better-than-expected Q4 results. On the news, JNJ stock is down -2.06%, selling …
23andMe Gives Customer Data to GlaxoSmithKlein
23andMe launched a DNA testing service in 2007. Since then, more than 5 million people have used the genomics service to find out about their biological inheritance.
With every application, 23andMe receives information …
Teva Pharmaceutical Reports Drop in Q3 Profit, Shares Plunge Almost 18%
Now might not be the time to get into the drug manufacturers industry. Well, maybe just don’t invest in Teva Pharmaceutical Industries (NYSE:$TEVA) for the time being.
On Thursday, after Teva Pharmaceutical – …
3 Reasons Behind Celgene Corp.’s Abysmal Q3 Earnings Report
On Thursday, Celgene Corp. (NASDAQ:$CELG) reported its Q3 earnings report- and let’s just say it did not go nearly as well as we hoped. Missing revenue by a whopping $120 million, Celgene has since plummeted …
Celgene Abandons Crohn’s Drug, Shares Drop to Four-Month Low
As of this morning, Celgene (NASDAQ:$CELG) shares have dropped to a four-month low, following scrapped trials in Crohn’s disease.
Celgene shares plunged as much as 10.9%, near 122.40. Shares hit a low last …
A Breakdown of Johnson & Johnson’s Major Sector Revenues Since 2Q17
As one of the largest pharmaceutical companies in the world, Johnson & Johnson (NASDAQ:$JNJ) operates in over 200 countries worldwide.
In 2Q17, the company reported revenues of $18.8 billion, a 2% increase from …
Pfizer Files Lawsuit Against Johnson & Johnson
Drugmaker giant Pfizer Inc. (NYSE:$PFE) has officially filed a lawsuit against Johnson & Johnson (NYSE:$JNJ) on claims that its rival’s contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales …
Pfizer’s Leukemia Drug Receives Green Light from FDA
The U.S. Food and Drug Administration officially approved Pfizer Inc’s (NYSE:$PFE) drug, Mylotarg, for the treatment of myeloid leukemia.
The drug was given the green ligt to treat adults with newly diagnosed AML …
New Era of Cancer Treatment: Watch Out for Gilead
On August 30th, the U.S. Food and Drug Administration (FDA) approved Novartis AG (NASDAQ:$NVS)’s leukemia treatment, the first time that a highly anticipated new type of potent gene-modifying immunotherapy has been approved in the United …